ALK-Abelló A/S (AKBLF)

Revenue by Product

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005
Sublingual Immunotherapy-Tablets	2.85B
Sublingual Immunotherapy-Tablets Growth	24.17%
Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops	2.05B
Subcutaneous Immunotherapy/Sublingual Immunotherapy-Drops Growth	5.83%
Other Products and Services	634.00M
Other Products and Services Growth	7.64%

Revenue by Geography

Financials in millions DKK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012	FY 2011	FY 2010	FY 2009	FY 2008	FY 2007	FY 2006	FY 2005
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016	Dec 31, 2015	Dec 31, 2014	Dec 31, 2013	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006	Dec 31, 2005
Europe	2.13B
Europe Growth	14.61%
Germany	978.50M
Germany Growth	38.30%
North America	779.16M
North America Growth	2.16%
International	717.00M
International Growth	13.81%
France	665.38M
France Growth	21.70%
Denmark	141.00M
Denmark Growth	35.58%
United States	126.84M
United States Growth	-12.69%